Physician profile
Peter S Margolis
NPI 1659457133
$7,555.73
in general payments reported to CMS, 2019-2025
25 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $413 · 2021: $803 · 2022: $926 · 2023: $1,552 · 2024: $1,672 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,709 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,709.09 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,617.08 | 2019-2025 | |
| Celgene Corporation | $585.95 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.62 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $518.21 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $443.73 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $401.59 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $237.07 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $188.73 | 2023-2025 | Voquezna |
| Novo Nordisk INC | $125.00 | 2023 | |
| Ethicon US, LLC | $122.00 | 2019 | |
| Boston Scientific Corporation | $100.00 | 2019 | |
| Ardelyx, INC. | $81.00 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $80.83 | 2023-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $80.15 | 2022-2023 | Rebyota |
| Madrigal Pharmaceuticals | $61.29 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.39 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $53.67 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $52.69 | 2019-2024 | Linzess |
| Pacira Pharmaceuticals Incorporated | $37.06 | 2021 | |
| Ucb, INC. | $36.96 | 2019 | |
| Amgen INC. | $27.98 | 2022 | |
| Genzyme Corporation | $27.88 | 2025 | |
| Merck Sharp & Dohme LLC | $14.91 | 2022 | |
| Orphalan INC | $14.39 | 2025 | Cuvrior |
| Daiichi Sankyo INC. | $13.55 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.